The Role of Sodium Chloride and the Treg/Th17 Axis in Autoimmune Hepatitis



Status:Recruiting
Conditions:Hepatitis
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:1 - 65
Updated:1/11/2018
Start Date:April 2013
End Date:June 2020

Use our guide to learn which trials are right for you!

The purpose of this study is to determine whether a salt restriction diet improves immune
parameters in patients with autoimmune hepatitis.

The etiology of autoimmune hepatitis (AIH) is unknown although both genetic and environmental
factors are thought to be involved. A defect in immune regulation affecting regulatory T
cells (Tregs) has been demonstrated in AIH. Tregs function in the maintenance of immune
homeostasis by controlling autoreactive immune responses to self-antigens.

Rationale: the western diet has been postulated as a potential environmental risk factor for
the increasing incidence of autoimmune diseases in developed countries. Data from the
investigators' laboratory also suggests that increased dietary salt intake might represent an
environmental risk factor for the development of autoimmune diseases through the induction of
pathogenic Th17 cells. The dramatic in vitro effects of high salt on the induction of
pathogenic Th17 cells from naïve human CD4 cells {Kleinewietfeld, Hafler. Nature. 2013 Apr
25;496(7446):518-22. doi: 10.1038/nature11868.}, and block of in vitro Treg suppression, in
line with in vivo effects on worsening murine experimental autoimmune encephalomyelitis
(EAE), have prompted the investigators to examine the effects of increased dietary sodium
chloride in a human in vivo system.

The investigators hypothesize that excess dietary salt may function as an environmental
trigger that favors induction and expansion of pathogenic Th17 cells and leads to functional
impairment of Tregs, thereby favoring development of autoimmunity. The investigators aim to
study their established in vitro model in humans by altering the salt intake in patients over
a 20-day period.

Inclusion Criteria:

- Adults 18-50 years of age

- Children 1-17 years of age

- ALT and/or ALP/GGT level > 2X upper limit of normal

- ANA or SMA >/= 1:40

- ANA or SMA >/= 1:80

- or LKM >/= 1:40

- or SLA positive

- IgG > upper limit of normal

Exclusion Criteria:

- Chronic hepatitis C

- Decompensated Liver Disease
We found this trial at
1
site
333 Cedar St
New Haven, Connecticut 06504
(203) 432-4771
Principal Investigator: Udeme Ekong, MD, MPH
Phone: 203-785-4649
Yale University School of Medicine Founded in 1810, the Yale School of Medicine is a...
?
mi
from
New Haven, CT
Click here to add this to my saved trials